These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26009617)

  • 1. Nonclinical models for antituberculosis drug development: a landscape analysis.
    Gumbo T; Lenaerts AJ; Hanna D; Romero K; Nuermberger E
    J Infect Dis; 2015 Jun; 211 Suppl 3():S83-95. PubMed ID: 26009617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
    Romero K; Clay R; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S5-9. PubMed ID: 26224771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.
    Gumbo T; Angulo-Barturen I; Ferrer-Bazaga S
    J Infect Dis; 2015 Jun; 211 Suppl 3():S96-S106. PubMed ID: 26009618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using animal models to develop new treatments for tuberculosis.
    Nuermberger E
    Semin Respir Crit Care Med; 2008 Oct; 29(5):542-51. PubMed ID: 18810687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.
    Chilukuri D; McMaster O; Bergman K; Colangelo P; Snow K; Toerner JG
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S32-3. PubMed ID: 26224770
    [No Abstract]   [Full Text] [Related]  

  • 7. Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
    Gumbo T; Pasipanodya JG; Romero K; Hanna D; Nuermberger E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S25-31. PubMed ID: 26224769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Models and approaches for anti-TB drug testing.
    Yasinskaya Y; Sacks L
    Expert Rev Anti Infect Ther; 2011 Jul; 9(7):823-31. PubMed ID: 21810054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug metabolism and drug interactions: potential application to antituberculosis drugs.
    Sahasrabudhe V; Zhu T; Vaz A; Tse S
    J Infect Dis; 2015 Jun; 211 Suppl 3():S107-14. PubMed ID: 26009614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Efficacy Testing of New Drug Candidates.
    Nuermberger EL
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28643624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Cavaleri M; Manolis E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
    Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
    Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of new antituberculosis drugs in mouse models.
    Davies GR; Pym AS; Mitchison DA; Nuermberger EL; Grosset JH
    Antimicrob Agents Chemother; 2007 Jan; 51(1):403; author reply 403-4. PubMed ID: 17182861
    [No Abstract]   [Full Text] [Related]  

  • 16. Dosing regimens in the treatment of tuberculosis.
    Blom-Bülow B
    Scand J Infect Dis Suppl; 1990; 74():258-61. PubMed ID: 2129066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical testing of new drugs for tuberculosis: current challenges.
    Lenaerts AJ; Degroote MA; Orme IM
    Trends Microbiol; 2008 Feb; 16(2):48-54. PubMed ID: 18182291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.
    Franzblau SG; DeGroote MA; Cho SH; Andries K; Nuermberger E; Orme IM; Mdluli K; Angulo-Barturen I; Dick T; Dartois V; Lenaerts AJ
    Tuberculosis (Edinb); 2012 Nov; 92(6):453-88. PubMed ID: 22940006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis.
    Ernest JP; Strydom N; Wang Q; Zhang N; Nuermberger E; Dartois V; Savic RM
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():495-516. PubMed ID: 32806997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Active drugs against Mycobacterium tuberculosis].
    Coll P
    Enferm Infecc Microbiol Clin; 2009 Oct; 27(8):474-80. PubMed ID: 19766360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.